{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:39Z","timestamp":1791924759991,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jocn.2017.07.014","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T16:45:17Z","timestamp":1501346717000},"page":"14-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Immune mediated neuropathy following checkpoint immunotherapy"],"prefix":"10.1016","volume":"45","author":[{"given":"Yufan","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Herkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2017.07.014_b0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","article-title":"Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer","volume":"11","author":"Drake","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jocn.2017.07.014_b0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jocn.2017.07.014_b0015","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2017.07.014_b0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/mus.23830","article-title":"Multifocal radiculoneuropathy during ipilimumab treatment of melanoma","volume":"48","author":"Manousakis","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jocn.2017.07.014_b0025","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2017.07.014_b0030","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1200\/JCO.2010.32.2206","article-title":"Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy","volume":"29","author":"Chmiel","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocn.2017.07.014_b0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2017.07.014_b0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2017.07.014_b0045","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2017.07.014_b0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2017.07.014_b0055","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jocn.2017.07.014_b0060","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.jocn.2017.07.014_b0065","doi-asserted-by":"crossref","unstructured":"Hughes RA, van Doorn PA. Corticosteroids for Guillain-Barre syndrome. The Cochrane database of systematic reviews. 2012:Cd001446.","DOI":"10.1002\/14651858.CD001446.pub4"},{"key":"10.1016\/j.jocn.2017.07.014_b0070","doi-asserted-by":"crossref","unstructured":"Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. The Cochrane database of systematic reviews. 2014:Cd002063.","DOI":"10.1002\/14651858.CD002063.pub6"},{"key":"10.1016\/j.jocn.2017.07.014_b0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/asheducation.V2012.1.7.3797920","article-title":"Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines","volume":"2012","author":"Winters","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.jocn.2017.07.014_b0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0165-5728(01)00255-7","article-title":"Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade enhances incidence and severity of experimental autoimmune neuritis in resistant mice","volume":"115","author":"Zhu","year":"2001","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jocn.2017.07.014_b0085","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586816311948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586816311948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T20:48:18Z","timestamp":1602622098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586816311948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":17,"alternative-id":["S0967586816311948"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2017.07.014","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune mediated neuropathy following checkpoint immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2017.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}